David Spellman
Geen lopende functies
Vermogen: - $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
LeAnne Zumwalt | F | 65 | 3 jaar | |
Ronald Frieson | M | 65 | 3 jaar | |
Willard Dere | M | 70 | 6 jaar | |
Tracey Vetterick | F | - | 2 jaar | |
Meredith Bowman | F | - | 2 jaar | |
Carolyn Rucci | F | - | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jason Amello | M | 55 | 7 jaar | |
James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 jaar |
Raymond T. Keane | M | 65 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 jaar |
Maxine Gowen | M | 66 | 7 jaar | |
Violetta Cotreau | F | 51 | 2 jaar | |
Sarah Carmody | F | - | 4 jaar | |
Elaine Jones | M | 69 | 3 jaar | |
Sara Nayeem | M | 75 | 6 jaar | |
Mark Enyedy | M | 60 | 3 jaar | |
Michael Heffernan | M | 59 | 4 jaar | |
David Noskowitz | M | - | 2 jaar | |
James Rosenthal | M | 70 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 jaar |
Donald Bergstrom | M | 52 | 4 jaar | |
Dirk Huebner | M | 61 | 2 jaar | |
Dell Faulkingham | M | 51 | - | |
Erin Colgan | F | 43 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 jaar |
Patrick Walsh | M | 41 | 6 jaar | |
Robert Copeland | M | - | 5 jaar | |
Kristie Wagner | F | 57 | 8 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 25 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- David Spellman
- Persoonlijk netwerk